Gary S. Leiserowitz

4.2k total citations
72 papers, 2.6k citations indexed

About

Gary S. Leiserowitz is a scholar working on Reproductive Medicine, Molecular Biology and Obstetrics and Gynecology. According to data from OpenAlex, Gary S. Leiserowitz has authored 72 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Reproductive Medicine, 21 papers in Molecular Biology and 19 papers in Obstetrics and Gynecology. Recurrent topics in Gary S. Leiserowitz's work include Ovarian cancer diagnosis and treatment (22 papers), Endometrial and Cervical Cancer Treatments (18 papers) and Glycosylation and Glycoproteins Research (12 papers). Gary S. Leiserowitz is often cited by papers focused on Ovarian cancer diagnosis and treatment (22 papers), Endometrial and Cervical Cancer Treatments (18 papers) and Glycosylation and Glycoproteins Research (12 papers). Gary S. Leiserowitz collaborates with scholars based in United States, Netherlands and South Korea. Gary S. Leiserowitz's co-authors include Rosemary D. Cress, Suzanne Miyamoto, Carlito B. Lebrilla, Lloyd H. Smith, Hyun Joo An, John L. Dalrymple, Cynthia D. O’Malley, Kit S. Lam, Scott Kronewitter and Maria Lorna A. De Leoz and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Bioinformatics.

In The Last Decade

Gary S. Leiserowitz

68 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary S. Leiserowitz United States	31	1.1k	884	606	592	423	72	2.6k
Benedict B. Benigno United States	27	1.1k 1.1×	702 0.8×	553 0.9×	229 0.4×	302 0.7×	61	2.4k
V R Zurawski United States	18	1.5k 1.5×	1.7k 1.9×	910 1.5×	442 0.7×	761 1.8×	26	4.3k
Vincent R. Zurawski United States	28	1.0k 1.0×	1.2k 1.4×	537 0.9×	390 0.7×	555 1.3×	44	3.2k
Eric L. Jenison United States	18	574 0.5×	1.5k 1.7×	578 1.0×	563 1.0×	591 1.4×	37	2.6k
Sarah Wheeler United States	25	935 0.9×	738 0.8×	977 1.6×	294 0.5×	553 1.3×	98	3.4k
Jonathan M. Niloff United States	24	1.2k 1.1×	2.9k 3.3×	860 1.4×	1.0k 1.7×	994 2.3×	47	4.8k
H.W.A. de Bruijn Netherlands	24	1.1k 1.0×	1.2k 1.3×	378 0.6×	583 1.0×	483 1.1×	66	2.8k
H. Boonstra Netherlands	24	476 0.5×	529 0.6×	537 0.9×	464 0.8×	447 1.1×	49	2.1k
Stephen A. Cannistra United States	30	2.0k 1.9×	2.0k 2.3×	1.9k 3.1×	475 0.8×	611 1.4×	46	5.1k
Ingo B. Runnebaum Germany	36	1.4k 1.3×	1.1k 1.3×	1.7k 2.8×	885 1.5×	843 2.0×	183	4.9k

Countries citing papers authored by Gary S. Leiserowitz

Since Specialization

Citations

This map shows the geographic impact of Gary S. Leiserowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary S. Leiserowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary S. Leiserowitz more than expected).

Fields of papers citing papers by Gary S. Leiserowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary S. Leiserowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary S. Leiserowitz. The network helps show where Gary S. Leiserowitz may publish in the future.

Co-authorship network of co-authors of Gary S. Leiserowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Gary S. Leiserowitz. A scholar is included among the top collaborators of Gary S. Leiserowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary S. Leiserowitz. Gary S. Leiserowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leiserowitz, Gary S., et al.. (2025). Patient Attitudes Toward Ambient Voice Technology: Preimplementation Patient Survey in an Academic Medical Center. JMIR Medical Informatics. 13. e77901–e77901.

Wamba, Brice E. N., Tanmoy Mondal, Daniel Bedinger, et al.. (2025). Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy. Nature Communications. 16(1). 5748–5748. 1 indexed citations

Fine, Jeffrey, et al.. (2023). Documentation of Infertility Risk Discussion in Cancer Patients Receiving Cancer-Directed Therapy: The UC Davis Cancer Center Experience. Journal of Adolescent and Young Adult Oncology. 13(2). 288–292. 1 indexed citations

Nguyen, Nancy, Dennis Montoya, Vincent Schilling, et al.. (2023). Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers. Gynecologic Oncology. 178. 69–79. 3 indexed citations

Mondal, Tanmoy, Brice E. N. Wamba, Salvatore Condello, et al.. (2023). Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer. Cell Death and Differentiation. 30(11). 2408–2431. 13 indexed citations

Rubin, Nicole, et al.. (2022). 5 Targeting NF1/RAS pathway mutations in high-grade serous ovarian carcinoma (HGSOC) with a novel dual-mechanism ERK 1/2 inhibitor to improve chemotherapy sensitivity. Gynecologic Oncology Reports. 44. S3–S3.

Mizenko, Rachel R., Tatu Rojalin, Hanna J. Koster, et al.. (2021). Tetraspanins are unevenly distributed across single extracellular vesicles and bias sensitivity to multiplexed cancer biomarkers. Journal of Nanobiotechnology. 19(1). 250–250. 106 indexed citations

Chen, Hui, Cristabelle De Souza, Clifford G. Tepper, et al.. (2020). Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma. Gynecologic Oncology. 157(3). 783–792. 50 indexed citations

Girda, Eugenia, Gary S. Leiserowitz, Lloyd H. Smith, & Eric C. Huang. (2017). The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible. International Journal of Gynecological Cancer. 27(8). 1701–1707. 57 indexed citations

10.

Leiserowitz, Gary S., et al.. (2017). Optimal perioperative anesthesia management for gynecologic interstitial brachytherapy. Journal of Contemporary Brachytherapy. 3(3). 216–223. 10 indexed citations

11.

Leiserowitz, Gary S., Jeff Lin, Ana I. Tergas, William A. Cliby, & Robert E. Bristow. (2017). Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study. International Journal of Gynecological Cancer. 27(4). 675–683. 18 indexed citations

12.

Kim, Kyoungmi, L. Renee Ruhaak, Uyen Thao Nguyen, et al.. (2014). Evaluation of Glycomic Profiling as a Diagnostic Biomarker for Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers & Prevention. 23(4). 611–621. 38 indexed citations

13.

Ruhaak, L. Renee, Sandra L. Taylor, Suzanne Miyamoto, et al.. (2013). Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. Analytical and Bioanalytical Chemistry. 405(14). 4953–4958. 32 indexed citations

14.

Hua, Serenus, Cynthia Williams, Lauren M. Dimapasoc, et al.. (2013). Isomer-specific chromatographic profiling yields highly sensitive and specific potential N-glycan biomarkers for epithelial ovarian cancer. Journal of Chromatography A. 1279. 58–67. 75 indexed citations

15.

Rodriguez, Anne O., et al.. (2005). Case report: Malignant peripheral nerve sheath tumor of the uterine cervix treated with radical vaginal trachelectomy. Gynecologic Oncology. 100(1). 201–204. 16 indexed citations

16.

Smith, Lloyd H., John L. Dalrymple, Gary S. Leiserowitz, Beate Danielsen, & William M. Gilbert. (2001). Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. American Journal of Obstetrics and Gynecology. 184(7). 1504–1513. 135 indexed citations

17.

Leiserowitz, Gary S., et al.. (1997). Detection of Serologic Neutralizing Antibodies against HPV-11 in Patients with Condyloma Acuminata and Cervical Dysplasia Using anin VitroAssay. Gynecologic Oncology. 66(2). 295–299. 10 indexed citations

18.

Leiserowitz, Gary S. & Michael Webb. (1996). Treatment of placental site trophoblastic tumor with hysterotomy and uterine reconstruction. Obstetrics and Gynecology. 88(4). 696–699. 31 indexed citations

19.

Smith, Lloyd H., Gary S. Leiserowitz, Kathleen Hall, et al.. (1995). Titration of HPV-11 Infectivity and Antibody Neutralization Can Be Measured In Vitro. Journal of Investigative Dermatology. 105(3). 438–444. 52 indexed citations

20.

Leiserowitz, Gary S., et al.. (1993). The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer. Gynecologic Oncology. 49(2). 190–196. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact